Recent research in ESCC revealed that upregulated expression of CCL2 could mediate TAMs accumulation via the CCL2-CCR2 signaling pathway, thereby inhibiting the anti-tumor ability of CTLs in TME and promoting immune evasion of ESCC cells (66). Here, CCR2 is linked to esophageal squamous cell carcinoma.